12,372 trials
Upper Respiratory Tract Infection · Nasal Congestion · Rhinorrhea
Primary: Physician Global Evaluation of Effectiveness on Nasal Symptoms — 1.9; 2.1 score on a scale
Acute Schizophrenia
Primary: Time From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse in Phase C. — 0.292; 3.420 Days — p=<0.0001
Schizophreniform Disorder · Schizoaffective Disorder · Psychosis
Primary: Weight Gain and Other Side Effects
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have · Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants
Rosacea · Erythema
Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065
Relapsing Multiple Sclerosis
Primary: Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs — 471; 478; 343; 348 participants
Angelman Syndrome
Primary: Bayley Cognitive Age Equivalent at 1 Year — 19; 19 months — p=0.75
Hepatitis C
Primary: Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12) — 99.2; 90.5 percentage of participants…
Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16 — 90.0 percentage of participants
Squamous Cell Carcinoma of the Head and Neck
Primary: Overall Survival (OS) — 7.49; 5.06 Months — p=0.0101
Acne
Primary: Absolute Change in Inflammatory Lesion Count — 16.3; 8.2 Lesion count
Dyspepsia · Helicobacter Pylori Infection
Primary: The Occurrence of H. Pylori Eradication as Confirmed Via 13C UBT Testing — 59; 1; 7; 36 Participants — p=0.001
Pancreatic Cancer
Primary: Percentage of Participants With Adverse Events (AEs) — 78.8 percentage of participants
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
Rheumatoid Arthritis
Primary: Percentage of Subjects With Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) <= 3.2 at Week 104 in RA0055 Period 2 Without Flaring — 39.2; 53.2…